Navigation Links
Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference
Date:7/30/2009

NEW YORK, July 30 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of oncology compounds directed to cancer stem cell targets, today announced that the Company's CEO, Ivan Bergstein M.D. has been invited to present at the New Frontiers in Cancer Drug Development conference which is part of IBC's Drug Discovery and Development Week in Boston, MA. Dr. Bergstein's presentation, entitled "Developing Drug Candidates Directed to Cancer Stem Cell Targets: Preclinical and Clinical Update" is scheduled for 9:50AM on Wednesday August 5(th) at the World Trade Center/Seaport Hotel in Boston. Dr. Bergstein has also been invited to participate in a panel discussion following the presentations.

Cancer stem cell targeted therapeutics have emerged as the next frontier in the fight against cancer. As such, this field is significantly influencing current decision making with respect to oncology drug development. With this in mind, Dr. Bergstein's presentation will cover novel pre-clinical and clinical development paradigms, including human trial design, of drug candidates that target cancer stem cells. The talk will also feature Stemline's latest clinical data, as well as results from its pre-clinical pipeline and drug discovery platforms.

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human clinical trial. Stemline is also developing a portfolio of biological and small molecule compounds directed at multiple high value cancer stem cell targets of a variety of hematological and solid cancers. Stemline has built a robust discovery platform called "StemScreen(R)" which the Company has utilized to identify multiple compounds that target and impair cancer stem cells. For more information, please visit the Company's website at www.stemline.com.

    Stemline Contact: Tom Cirrito, PhD, Director of Operations, Stemline
    Therapeutics, Inc. Tel: 212-531-5976; Email: tcirrito@stemline.com


'/>"/>
SOURCE Stemline Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Stemline Therapeutics Raises $12.5 Million
2. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
3. Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date
4. PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
5. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
6. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
7. Cell Therapeutics, Inc. Announces Exercise of Overallotment
8. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
9. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
10. Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics
11. Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/25/2017)... City, New York (PRWEB) , ... February 25, ... ... their partnership with Verified Clinical Trials in an ongoing effort to ... areas of treatment, advocacy, and pharmaceutical research with emphasis on consumers and patients’ ...
(Date:2/24/2017)... ... , ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today ... (NIMH) for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ). ... deliver therapeutic levels of olanzapine for a period of 3 months., “We are honored ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... the deadline to participate in its previously announced ... consisting of shares of common stock and Series ... holders of listed warrants. As ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, ... developing a new category of therapeutics, announced today the ... SB-030 in peripheral artery disease. The trial will evaluate ... single-use therapeutic, in the reduction of restenosis following angioplasty. ... critical development milestone for SB-030," said Nathan Bachtell ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. ... the Avamere Family of Companies (Avamere Health Services, Infinity ... a six-month research study that will apply the power ... at senior living and health centers. By analyzing data ... to gain insights into physical and environmental conditions, and ...
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice Recognition ... to match it against a stored voiceprint template. ... pitch, cadence, and tone are compared to distinguish ... hardware installation, as most PCs already have a ... transactions. Voice recognition biometrics are most likely to ...
Breaking Biology News(10 mins):